-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
High levels of mucosal antibodies in the airways reduce the risk of being infected by omicron, but despite three doses of the SARS-CoV-2 vaccine, many people still do not receive detectable antibodies
The COMMUNITY study recruited 2149 health care workers
The level of respiratory mucosal IgA antibodies (immunoglobulin A) is measured because they play an important role
"It's not surprising that antibodies in the respiratory tract neutralize the virus locally, but these findings suggest for the first time that SARS-CoV-2 mucosal antibodies in the respiratory tract can actually prevent small particle infections," said lead author of the study, Charlotte M.
Higher mucosal antibodies in the respiratory tract were also associated
The researchers also showed that participants who had been infected with SARS-CoV-2 before vaccination had significantly higher
Charlotte Th?lin said: "Although we have received several doses of today's intramuscular vaccination, we are now in a situation where
COMMUNITY research continues to take regular samples from the blood and mucous membranes to monitor recurrent infections and the immune response
The study was funded
